CN107531675A - 治疗活性化合物及其使用方法 - Google Patents

治疗活性化合物及其使用方法 Download PDF

Info

Publication number
CN107531675A
CN107531675A CN201680020656.7A CN201680020656A CN107531675A CN 107531675 A CN107531675 A CN 107531675A CN 201680020656 A CN201680020656 A CN 201680020656A CN 107531675 A CN107531675 A CN 107531675A
Authority
CN
China
Prior art keywords
compound
dose
idh2
day
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680020656.7A
Other languages
English (en)
Chinese (zh)
Inventor
斯特凡·克鲁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CN107531675A publication Critical patent/CN107531675A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680020656.7A 2015-02-04 2016-02-03 治疗活性化合物及其使用方法 Pending CN107531675A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112127P 2015-02-04 2015-02-04
US62/112,127 2015-02-04
PCT/US2016/016335 WO2016126798A1 (en) 2015-02-04 2016-02-03 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
CN107531675A true CN107531675A (zh) 2018-01-02

Family

ID=55640843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680020656.7A Pending CN107531675A (zh) 2015-02-04 2016-02-03 治疗活性化合物及其使用方法

Country Status (8)

Country Link
US (2) US10201543B2 (https=)
EP (1) EP3253746A1 (https=)
JP (3) JP7220986B6 (https=)
KR (1) KR102628370B1 (https=)
CN (1) CN107531675A (https=)
CA (1) CA2975506A1 (https=)
IL (1) IL253796A0 (https=)
WO (1) WO2016126798A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014295938B2 (en) 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
JP2017529382A (ja) 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10695352B2 (en) 2015-10-15 2020-06-30 Celgene Corporation Combination therapy for treating malignancies
KR20180063125A (ko) 2015-10-15 2018-06-11 아지오스 파마슈티컬스 아이엔씨. 악성종양을 치료하기 위한 복합 요법
ES2905915T3 (es) 2015-12-04 2022-04-12 Servier Lab Procedimientos de tratamiento de neoplasias malignas
MA43640A (fr) 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
JP7093764B2 (ja) * 2016-08-03 2022-06-30 セルジーン コーポレイション 骨髄異形成症候群の治療方法
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.
WO2018204787A1 (en) 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US20220017490A1 (en) * 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
JP2023503842A (ja) * 2019-11-14 2023-02-01 セルジーン コーポレーション がんを処置するための小児用製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
CN104114543A (zh) * 2012-01-06 2014-10-22 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
AU2014295938B2 (en) 2013-08-02 2018-07-19 Les Laboratoires Servier Therapeutically active compounds and their methods of use
JP2017529382A (ja) * 2014-09-29 2017-10-05 アギオス ファーマシューティカルス，インコーポレーテッド 治療活性を有する化合物及びその使用方法
JP7220986B6 (ja) * 2015-02-04 2024-02-08 アジオス ファーマシューティカルズ， インコーポレイテッド 治療効果のある化合物及びその使用方法
US9751863B2 (en) 2015-08-05 2017-09-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR20180063125A (ko) 2015-10-15 2018-06-11 아지오스 파마슈티컬스 아이엔씨. 악성종양을 치료하기 위한 복합 요법
ES2905915T3 (es) 2015-12-04 2022-04-12 Servier Lab Procedimientos de tratamiento de neoplasias malignas
MA43640A (fr) 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
EP3493809B1 (en) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
MX392941B (es) 2016-09-07 2025-03-24 Celgene Corp Composiciones para comprimidos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
CN104114543A (zh) * 2012-01-06 2014-10-22 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途

Also Published As

Publication number Publication date
US20180028539A1 (en) 2018-02-01
JP2023011792A (ja) 2023-01-24
JP7220986B6 (ja) 2024-02-08
US10201543B2 (en) 2019-02-12
US10434105B2 (en) 2019-10-08
US20190117662A1 (en) 2019-04-25
WO2016126798A1 (en) 2016-08-11
JP2018504429A (ja) 2018-02-15
CA2975506A1 (en) 2016-08-11
JP7220986B2 (ja) 2023-02-13
IL253796A0 (en) 2017-09-28
KR20170113628A (ko) 2017-10-12
KR102628370B1 (ko) 2024-01-24
JP2021038227A (ja) 2021-03-11
EP3253746A1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
US20260085059A1 (en) Therapeutically active compounds and their methods of use
US10434105B2 (en) Therapeutically active compounds and their methods of use
KR102316886B1 (ko) 치료학적 활성 화합물 및 이의 사용방법
HK40016190A (en) Therapeutically active compounds and their methods of use
HK40016189A (en) Therapeutically active compounds and their methods of use
HK40016189B (en) Therapeutically active compounds and their methods of use
HK40016900A (en) Therapeutically active compounds and their methods of use
HK40016900B (en) Therapeutically active compounds and their methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102